Back HCV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

Gene Variation Linked to Liver Cancer in Hepatitis C Patients

A genome-wide association study looking at more than 460,000 single nucleotide changes found that a variation in the DEPDC5 gene on chromosome 22 is associated with increased risk of hepatocellular carcinoma in people with hepatitis C.

Read more:

Screening for Liver Cancer in HIV/HCV Coinfected People

Nearly half of HIV/HCV coinfected individuals with liver cancer in an international study were never screened for hepatocellular carcinoma, but those who did undergo screening had their cancer detected at an earlier stage, leading to more effective treatment and improved survival, according to a report presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna.

Read more:

A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy

Over years or decades, chronic hepatitis C virus (HCV) infection can lead to advanced liver disease, including cirrhosis and hepatocellular carcinoma (HCC). Sustained response to interferon-based therapy dramatically reduces the risk of liver disease progression, but does not eliminate it completely, according to 2 recently published studies.

Read more:

Chronic Hepatitis C Complications are Increasing, Especially among People Older than 60 Years

The proportion of people with chronic hepatitis C virus (HCV) infection who will develop advanced liver disease including cirrhosis, decompensation, and liver cancer is likely to increase over the next 10-20 years as people infected decades ago reach the stage of developing advanced disease; these complications are expected to be especially common among people over age 60. But more widespread treatment could significantly lower projected rates of disease progression, according to a study published in the February 2010 issue of Gastroenterology.

Read more:

Two Studies Look at Promising Therapies for Liver Cancer: Sorafenib and Doxorubicin

Two recently published studies produced promising data on experimental therapies for HCC: the systemic chemotherapy drug sorafenib (Nexavar), and combination therapy using doxorubicin-eluting beads plus radiofrequency ablation.


Read more: